Inscripta, Inc., a Boulder, CO-based digital genome engineering company, closed a $150m Series E financing.
The round was led by Fidelity Management & Research Company LLC and funds and accounts advised by T. Rowe Price Associates, Inc., with participation from new investors D1 Capital Partners and Durable Capital Partners LP, as well as existing investors Foresite Capital, Counterpoint Global (Morgan Stanley), and JS Capital LLC.
Led by Sri Kosaraju, President and CEO, Inscripta provides the Onyx platform, which is a benchtop system for scalable digital genome engineering and consists of a benchtop instrument, consumables, software and assays. With a fully automated CRISPR-based workflow, the platform enables massively parallel, trackable editing of single cells at scale.
The company also has offices in San Diego and Pleasanton, Calif., and Copenhagen, Denmark.